SearchDictionaryMobileLogin

P Hugh R Barrett Selected Research

Syndrome

10/2008Atorvastatin and Fenofibrate Have Comparable Effects on VLDL-Apolipoprotein C-III Kinetics in Men With the Metabolic Syndrome.
08/2008Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome.
03/2008Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome.
02/2008Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome.
11/2007Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels.
01/2007Dietary plant sterols supplementation does not alter lipoprotein kinetics in men with the metabolic syndrome.
09/2006Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome.
03/2006High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics.
02/2006Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders.
09/2004Lipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies.
09/2004Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods.
02/2004Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies.
04/2003Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
04/2003Relationships between cholesterol homoeostasis and triacylglycerol-rich lipoprotein remnant metabolism in the metabolic syndrome.
03/2003Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
02/2003Kinetic studies of lipoprotein metabolism in the metabolic syndrome including effects of nutritional interventions.

Articles by Research Topic

Disease

16Syndrome
10/2008 - 02/2003
7Obesity
07/2006 - 05/2002
3Overweight
09/2005 - 01/2003
2Weight Loss (Weight Reduction)
11/2007 - 02/2003
2Hypobetalipoproteinemias (Hypobetalipoproteinemia)
08/2007 - 04/2007
2Hyperlipidemias (Hyperlipidemia)
02/2003 - 09/2002
1Malaria
12/2007
1Insulin Resistance
03/2005
1Atherosclerosis (Atheroma)
11/2004
1Chronic Kidney Failure (Chronic Renal Failure)
03/2004
1Vivax Malaria
04/2003
1Dyslipidemias (Dyslipidemia)
08/2002
1Falciparum Malaria (Plasmodium falciparum Malaria)
07/2002
1Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
03/2002

Drug/Important Bio-Agent (IBA)

15Lipoproteins (Lipoprotein)IBA
02/2008 - 02/2003
12Apolipoprotein B-100 (Apo B 100)IBA
03/2008 - 03/2002
6atorvastatin (Lipitor)FDA Link
10/2008 - 05/2002
3Procetofen (CiL)FDA LinkGeneric
10/2008 - 03/2003
3Apolipoprotein C-IIIIBA
10/2008 - 08/2002
3rosuvastatin (Crestor)FDA Link
08/2008 - 02/2008
2AdiponectinIBA
11/2007 - 03/2005
2CholesterolIBA
04/2003 - 04/2003
2Chylomicron RemnantsIBA
02/2003 - 05/2002
2LDL Receptors (LDL Receptor)IBA
02/2003 - 03/2002
1dihydroquinghaosu (dihydroartemisinin)IBA
12/2007
1Vitamin A (Retinol)FDA Link
11/2007
1Apolipoproteins B (ApoB)IBA
08/2007
1Phytosterols (Plant Sterols)IBA
01/2007
1Proteins (Proteins, Gene)IBA
09/2006
1Apolipoproteins AIBA
07/2006
1Apolipoprotein A-I (Apolipoprotein A1)IBA
06/2005
1AdipokinesIBA
03/2005
1biglycanIBA
11/2004
1Chloroquine (Aralen)FDA LinkGeneric
04/2003
1Triglycerides (Triacylglycerol)IBA
04/2003
1Apolipoproteins E (ApoE)IBA
09/2002
1Insulin (Novolin)FDA Link
08/2002
1Hydroxymethylglutaryl CoA Reductases (HMG CoA Reductase)IBA
08/2002
1Fish OilsIBA
08/2002
1Glucose (Dextrose)FDA LinkGeneric
07/2002
1Lactic AcidFDA LinkGeneric
07/2002
1C-Reactive ProteinIBA
06/2002
1OxidoreductasesIBA
05/2002
1Coenzyme A (CoA)IBA
05/2002

Therapy/Procedure

1Peritoneal Dialysis
03/2004